Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Tonix Pharma ( (TNXP) ) is now available.
On June 16, 2025, Tonix Pharmaceuticals presented data at the Annual European Congress of Rheumatology, highlighting their product TNX-102 SL, which targets non-restorative sleep and provides sustained pain reduction for fibromyalgia treatment. This presentation underscores Tonix’s ongoing efforts to enhance fibromyalgia treatment options, potentially strengthening their position in the pharmaceutical market and impacting stakeholders interested in innovative pain management solutions.
The most recent analyst rating on (TNXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
Tonix Pharma’s stock score is mainly driven by positive technical indicators and promising corporate events, which are offset by weak profitability and valuation metrics. The company’s solid growth prospects in biotechnology and recent strategic initiatives support a moderate outlook.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. operates in the pharmaceutical industry, focusing on the development of innovative therapies for central nervous system disorders, immunology, and infectious diseases. The company is particularly known for its work on treatments for conditions such as fibromyalgia, with a market focus on addressing unmet medical needs.
Average Trading Volume: 1,221,110
Technical Sentiment Signal: Sell
Current Market Cap: $235.3M
For a thorough assessment of TNXP stock, go to TipRanks’ Stock Analysis page.